While Rigel Pharmaceuticals has overperformed by 5.24%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RIGL rose by 137.46%, with highs and lows ranging from $43.72 to $14.63, whereas the simple moving average jumped by 61.88% in the last 200 days.
On November 05, 2025, Jefferies Upgraded Rigel Pharmaceuticals (NASDAQ: RIGL) to Buy. Piper Sandler June 08, 2022d the rating to Neutral on June 08, 2022, and set its price target from $7 to $1. Cantor Fitzgerald June 08, 2022d its ‘Overweight’ rating to ‘Neutral’ for RIGL, as published in its report on June 08, 2022. B. Riley Securities’s report from March 23, 2022 suggests a price prediction of $4 for RIGL shares, giving the stock a ‘Neutral’ rating. JP Morgan also rated the stock as ‘Neutral’.
Analysis of Rigel Pharmaceuticals (RIGL)
Further, the quarter-over-quarter increase in sales is 25.59%, showing a positive trend in the upcoming months.
One of the most important indicators of Rigel Pharmaceuticals’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of 220.06% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.14, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and RIGL is recording 696.49K average volume. On a monthly basis, the volatility of the stock is set at 6.24%, whereas on a weekly basis, it is put at 6.85%, with a gain of 5.52% over the past seven days. Furthermore, long-term investors anticipate a median target price of $46.60, showing growth from the present price of $39.94, which can serve as yet another indication of whether RIGL is worth investing in or should be passed over.
How Do You Analyze Rigel Pharmaceuticals Shares?
The Biotechnology market is dominated by Rigel Pharmaceuticals (RIGL) based in the USA. When comparing Rigel Pharmaceuticals shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 6.48, there is a growth in quarterly earnings of 106.95%.
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.70%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 70.16% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
